A Potential Therapeutic Strategy Involving Short-Term Prednisone and Methotrexate for Patients with Polymyalgia Rheumatica - Takeaways - MDSpire

A Potential Therapeutic Strategy Involving Short-Term Prednisone and Methotrexate for Patients with Polymyalgia Rheumatica

  • By

  • Edoardo Conticini

  • Raffaele Truscelli

  • Silvia Grazzini

  • Paolo Falsetti

  • Caterina Baldi

  • Alessandra Cartocci

  • Luca Cantarini

  • Bruno Frediani

  • February 26, 2026

  • 0 min

Share

  • 1

    Polymyalgia rheumatica (PMR) is a common inflammatory condition in the elderly, often requiring long-term glucocorticoid treatment.

  • 2

    The study investigates the efficacy of short-term prednisone combined with methotrexate in newly diagnosed PMR patients.

  • 3

    Patients with subclinical giant cell arteritis were excluded to ensure accurate assessment of treatment response.

  • 4

    The primary endpoint was prednisone-free remission at 26 weeks, with secondary endpoints including sustained remission at 52 weeks.

  • 5

    Results indicated that early methotrexate administration may provide a safe and effective treatment strategy for PMR.

Original Source(s)

A Potential Therapeutic Strategy Involving Short-Term Prednisone and Methotrexate for Patients with Polymyalgia Rheumatica

  • by Edoardo Conticini, Raffaele Truscelli, Silvia Grazzini, Paolo Falsetti, Caterina Baldi, Alessandra Cartocci, Luca Cantarini, Bruno Frediani

  • February 26, 2026

Related Content

Neutrophil extracellular traps and pyroptosis: a molecular nexus linking systemic autoimmune diseases to atherosclerosis

Ultrasound Models Estimate Whole-Body Muscle Mass

New equations incorporating cross-sectional area improve estimation accuracy.

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.